vs

Side-by-side financial comparison of BXP, Inc. (BXP) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.

BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $872.1M, roughly 1.7× BXP, Inc.). BXP, Inc. runs the higher net margin — 15.3% vs 4.4%, a 10.8% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 0.8%). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 1.3%).

BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

BXP vs ONC — Head-to-Head

Bigger by revenue
ONC
ONC
1.7× larger
ONC
$1.5B
$872.1M
BXP
Growing faster (revenue YoY)
ONC
ONC
+32.0% gap
ONC
32.8%
0.8%
BXP
Higher net margin
BXP
BXP
10.8% more per $
BXP
15.3%
4.4%
ONC
Faster 2-yr revenue CAGR
ONC
ONC
Annualised
ONC
41.2%
1.3%
BXP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BXP
BXP
ONC
ONC
Revenue
$872.1M
$1.5B
Net Profit
$133.0M
$66.5M
Gross Margin
90.5%
Operating Margin
12.4%
Net Margin
15.3%
4.4%
Revenue YoY
0.8%
32.8%
Net Profit YoY
53.0%
143.8%
EPS (diluted)
$1.69
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BXP
BXP
ONC
ONC
Q1 26
$872.1M
Q4 25
$877.1M
$1.5B
Q3 25
$871.5M
$1.4B
Q2 25
$868.5M
$1.3B
Q1 25
$865.2M
$1.1B
Q4 24
$858.6M
$1.1B
Q3 24
$859.2M
$1.0B
Q2 24
$850.5M
$929.2M
Net Profit
BXP
BXP
ONC
ONC
Q1 26
$133.0M
Q4 25
$248.4M
$66.5M
Q3 25
$-121.7M
$124.8M
Q2 25
$89.0M
$94.3M
Q1 25
$61.2M
$1.3M
Q4 24
$-228.9M
$-151.9M
Q3 24
$83.6M
$-121.3M
Q2 24
$79.6M
$-120.4M
Gross Margin
BXP
BXP
ONC
ONC
Q1 26
Q4 25
58.8%
90.5%
Q3 25
59.3%
86.1%
Q2 25
59.2%
87.5%
Q1 25
59.2%
85.2%
Q4 24
59.7%
85.8%
Q3 24
59.5%
83.0%
Q2 24
59.8%
85.1%
Operating Margin
BXP
BXP
ONC
ONC
Q1 26
Q4 25
12.4%
Q3 25
11.5%
Q2 25
6.7%
Q1 25
1.0%
Q4 24
-7.0%
Q3 24
-12.0%
Q2 24
-11.5%
Net Margin
BXP
BXP
ONC
ONC
Q1 26
15.3%
Q4 25
28.3%
4.4%
Q3 25
-14.0%
8.8%
Q2 25
10.2%
7.2%
Q1 25
7.1%
0.1%
Q4 24
-26.7%
-13.5%
Q3 24
9.7%
-12.1%
Q2 24
9.4%
-13.0%
EPS (diluted)
BXP
BXP
ONC
ONC
Q1 26
$1.69
Q4 25
$1.56
$0.05
Q3 25
$-0.77
$0.08
Q2 25
$0.56
$0.06
Q1 25
$0.39
$0.00
Q4 24
$-1.46
$-0.10
Q3 24
$0.53
$-0.09
Q2 24
$0.51
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BXP
BXP
ONC
ONC
Cash + ST InvestmentsLiquidity on hand
$512.8M
$4.5B
Total DebtLower is stronger
$836.4M
Stockholders' EquityBook value
$7.7B
$4.4B
Total Assets
$25.1B
$8.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BXP
BXP
ONC
ONC
Q1 26
$512.8M
Q4 25
$1.5B
$4.5B
Q3 25
$861.1M
$4.0B
Q2 25
$447.0M
$2.8B
Q1 25
$398.1M
$2.5B
Q4 24
$1.3B
$2.6B
Q3 24
$1.4B
$2.7B
Q2 24
$685.4M
$2.6B
Total Debt
BXP
BXP
ONC
ONC
Q1 26
Q4 25
$836.4M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BXP
BXP
ONC
ONC
Q1 26
$7.7B
Q4 25
$5.1B
$4.4B
Q3 25
$5.0B
$4.1B
Q2 25
$5.3B
$3.8B
Q1 25
$5.3B
$3.5B
Q4 24
$5.4B
$3.3B
Q3 24
$5.8B
$3.4B
Q2 24
$5.8B
$3.4B
Total Assets
BXP
BXP
ONC
ONC
Q1 26
$25.1B
Q4 25
$26.2B
$8.2B
Q3 25
$26.0B
$7.6B
Q2 25
$25.6B
$6.3B
Q1 25
$25.4B
$5.8B
Q4 24
$26.1B
$5.9B
Q3 24
$26.4B
$5.8B
Q2 24
$25.5B
$5.7B
Debt / Equity
BXP
BXP
ONC
ONC
Q1 26
Q4 25
0.19×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BXP
BXP
ONC
ONC
Operating Cash FlowLast quarter
$417.3M
Free Cash FlowOCF − Capex
$379.8M
FCF MarginFCF / Revenue
25.4%
Capex IntensityCapex / Revenue
1.5%
2.5%
Cash ConversionOCF / Net Profit
6.28×
TTM Free Cash FlowTrailing 4 quarters
$941.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BXP
BXP
ONC
ONC
Q1 26
Q4 25
$407.8M
$417.3M
Q3 25
$274.2M
$402.6M
Q2 25
$353.1M
$263.6M
Q1 25
$210.0M
$44.1M
Q4 24
$383.7M
$75.2M
Q3 24
$286.1M
$188.4M
Q2 24
$367.1M
$-95.6M
Free Cash Flow
BXP
BXP
ONC
ONC
Q1 26
Q4 25
$362.7M
$379.8M
Q3 25
$231.6M
$354.5M
Q2 25
$281.5M
$219.8M
Q1 25
$152.6M
$-12.3M
Q4 24
$312.5M
$-17.3M
Q3 24
$234.5M
$54.7M
Q2 24
$332.4M
$-205.5M
FCF Margin
BXP
BXP
ONC
ONC
Q1 26
Q4 25
41.4%
25.4%
Q3 25
26.6%
25.1%
Q2 25
32.4%
16.7%
Q1 25
17.6%
-1.1%
Q4 24
36.4%
-1.5%
Q3 24
27.3%
5.5%
Q2 24
39.1%
-22.1%
Capex Intensity
BXP
BXP
ONC
ONC
Q1 26
1.5%
Q4 25
5.1%
2.5%
Q3 25
4.9%
3.4%
Q2 25
8.2%
3.3%
Q1 25
6.6%
5.0%
Q4 24
8.3%
8.2%
Q3 24
6.0%
13.3%
Q2 24
4.1%
11.8%
Cash Conversion
BXP
BXP
ONC
ONC
Q1 26
Q4 25
1.64×
6.28×
Q3 25
3.22×
Q2 25
3.97×
2.79×
Q1 25
3.43×
34.71×
Q4 24
Q3 24
3.42×
Q2 24
4.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BXP
BXP

Lease$818.2M94%
Parking and other$30.8M4%
Development and management services$9.2M1%

ONC
ONC

Segment breakdown not available.

Related Comparisons